Skip to main content
OpenTrials
Completed

NCT Number: NCT05171855

A Trial to Investigate Long Term Efficacy and Safety of Lonapegsomatropin in Adults With Growth Hormone Deficiency

This was a phase 3 open-label multicenter extension study designed to evaluate the long-term safety and efficacy of Lonapegsomatropin administered once-weekly. The study participants were adults (males and females) with confirmed growth hormone deficiency (GHD) having completed the treatment period in study TCH-306 (foresiGHt; NCT04615273).

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Adult Growth Hormone Deficiency Bone Diseases Bone Diseases, Developmental Bone Diseases, Endocrine Brain Diseases Central Nervous System Diseases Dwarfism Dwarfism, Pituitary Endocrine System Diseases Hormone Deficiency Hypopituitarism Hypothalamic Diseases Musculoskeletal Diseases Nervous System Diseases Pituitary Diseases

Age range

23 year–81 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 3

Primary location

Ascendis Pharma Investigational Site, Yerevan, Armenia

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Signing of the trial specific informed consent
  • Completion of the treatment period and Visit 7 assessments of trial TCH-306, including collection and upload of Visit 7 dual-X-ray-absorptiometry (DXA) scan
  • Fundoscopy at Visit 7 in trial TCH-306 without signs/symptoms of intracranial hypertension or diabetic retinopathy stage 2 / moderate or above

Exclusion criteria

  • Diabetes mellitus if any of the following were met:
  • Poorly controlled diabetes, defined as HbA1C higher than 7.5% according to central laboratory at Visit 7 in trial TCH-306
  • Use of diabetes mellitus drugs other than metformin and/or dipeptidyl peptidase-4 (DPP-4) inhibitors
  • Active malignant disease or history of malignancy.
  • Known history of hypersensitivity and/or idiosyncrasy to the investigational product (somatropin or excipients)
  • Female who was pregnant, plans to become pregnant, or was breastfeeding
  • Female participant of childbearing potential (i.e., fertile, following menarche and until becoming post-menopausal unless permanently sterile) not willing throughout the trial to use contraceptives as required by local law or practice. Details included in Appendix 4/section 10.4 of the protocol
  • Male participant not willing throughout the trial to use contraceptives as required by local law or practice. Details included in Appendix 4/ section 10.4 of the protocol
  • Any disease or condition that, in the judgement of the investigator, may make the participant unlikely to comply with the requirements of the protocol or any condition that presents undue risk from the investigational product or trial procedures

Treatment and study plan

Lonapegsomatropin

Drug

Study participants were individually dosed with subcutaneous injection of Lonapegsomatropin once-weekly for 52 weeks.

Other names: ACP-011

Primary outcomes

  1. Number of Participants With Treatment-Emergent Adverse Events (TEAEs), Serious TEAEs and TEAE Leading to Study Discontinuation

    Time frame: Up to 52 Weeks

    An Adverse Event (AE) was defined as any untoward medical occurrence in a clinical investigation participant administered a pharmaceutical product and which did not necessarily have a causal relationship with the treatment. An AE was considered a TEAE if it occurred on or after the first dose of investigational product and was not present prior to the first dose, or it was present at the first dose but increased in severity during the trial. A serious AE was any untoward medical occurrence at any dose that met any of the following criteria: resulted in death; was life threatening; required or prolonged inpatient hospitalization; resulted in persistent or significant disability/incapacity; resulted in a congenital anomaly/birth defect in a neonate/infant born to a mother exposed to the trial drug or was considered a significant medical event by the investigator.

Secondary outcomes

  1. Change From Baseline in Trunk Percent Fat at Week 52

    Time frame: Baseline main trial to week 52 (extension period)

    Trunk percent fat was assessed by dual-energy X-ray absorptiometry.

  2. Change From Baseline in Trunk Fat Mass at Week 52

    Time frame: Baseline main trial to week 52 (extension period)

    Trunk fat mass was assessed by dual-energy X-ray absorptiometry.

  3. Change From Baseline in Total Body Lean Mass at Week 52

    Time frame: Baseline main trial to week 52 (extension period)

    Total body lean mass was assessed by dual-energy X-ray absorptiometry.

Sponsors and collaborators

Lead sponsor

Ascendis Pharma Endocrinology Division A/S

Industry

Registry information

Official study title

A Multicenter, Open-Label, Extension Trial to Investigate Long Term Efficacy and Safety of Lonapegsomatropin in Adults With Growth Hormone Deficiency

Important dates

Study start
2021
Primary completion
2024
Study completion
2024
First posted
Dec 29, 2021
Registry last updated
Jul 7, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.